PPIDT00386
Drug Information
| Name | Eptinezumab |
|---|---|
| Sequence | EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMNWVRQAPGKGLEWVGVIGINGATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDARVEPKSCDKTHTCPPCPAPELLGGPSVTLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB14040 |
| Type | biotech |
| Indication | Eptinezumab is indicated for the preventive treatment of migraine in adults.[L12318] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
100 mg/1mL
|
| Injection, solution, concentrate | Intravenous |
100 mg
|
| Injection, solution, concentrate | Intravenous |
300 mg
|
| Solution | Intravenous |
100 mg / mL
|
| Solution | Intravenous |
100.00 mg
|
| Solution | Intravenous |
300 mg / 3 mL
|
| Solution | Intravenous drip |
100 MG/ML
|
| Injection, solution, concentrate | Intravenous |
100 mg/mL
|